Article Dans Une Revue (Article De Synthèse) Pneumonia Année : 2023

Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection

Résumé

Pneumococcal conjugate vaccines (PCVs) provide protection against vaccine-type pneumococcal disease in both children and adults. Growing evidence suggests that PCVs also reduce pneumonia and lower respiratory tract infections (LRTIs) more broadly, including protecting against viral-associated respiratory diseases. In this short narrative review, we highlight clinical studies investigating whether PCVs might have a role in reducing coronavirus disease, both those caused by endemic human coronaviruses (HCoVs) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). These studies include two randomized controlled trials assessing HCoV-associated pneumonia, one each in children and older adults, and two observational studies of PCV13 effectiveness against HCoV-associated LRTI and COVID-19 in adults. We discuss possible mechanisms for PCV protection including preventing viral pneumococcal co-infections and the possibility that pneumococci in the upper respiratory tract might modify the host immune response to SARS-CoV-2. Lastly, we identify knowledge gaps and further questions on the potential role of PCVs during the COVID-19 pandemic.
Fichier principal
Vignette du fichier
Dunne, Pneumonia, 2023.pdf (891) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
licence

Dates et versions

hal-04901052 , version 1 (20-01-2025)

Licence

Identifiants

Citer

Eileen M Dunne, Marta C Nunes, Mary P E Slack, Christian Theilacker, Bradford D Gessner. Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection. Pneumonia, 2023, 15 (1), pp.10. ⟨10.1186/s41479-023-00112-w⟩. ⟨hal-04901052⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More